NOVARTIS

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public, Private

Established: 1996-01-01

Employees: 76K

Market Cap: $242.6B

Website: https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Clinical Trials

Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis

Phase 4

Terminated

Conditions: Gastroparesis
Diabetes

First Posted Date: 2006-10-23

Last Posted Date: 2012-05-04

Lead Sponsor: Novartis

Target Recruit Count: 40

Registration Number: NCT00390975

Locations: 🇺🇸
The University of Kansas Medical Center, Kansas City, Kansas, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
The University of Louisville, Louisville, Kentucky, United States

Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2006-10-20

Last Posted Date: 2020-02-11

Lead Sponsor: Novartis

Target Recruit Count: 28

Registration Number: NCT00390520

Locations: 🇨🇭
Novartis, Basel, Switzerland

Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn

Phase 3

Completed

Conditions: Heartburn

First Posted Date: 2006-10-19

Last Posted Date: 2007-04-16

Lead Sponsor: Novartis

Target Recruit Count: 576

Registration Number: NCT00389948

Locations: 🇺🇸
William W. Anderson M.D. P.C., Rio Rancho, New Mexico, United States
🇺🇸
Benchmark Research, San Angelo, Texas, United States
🇺🇸
Micheal Alexander, DO, Columbus, Ohio, United States

and more 19 locations

Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn

Phase 3

Completed

Conditions: Heartburn

First Posted Date: 2006-10-19

Last Posted Date: 2010-05-25

Lead Sponsor: Novartis

Target Recruit Count: 576

Registration Number: NCT00390390

Locations: 🇺🇸
Palm Beach Research, West Palm Beach, Florida, United States
🇺🇸
Medical Edge Healthcare Group, Dallas, Texas, United States
🇺🇸
Gaslamp Medical Center, San Diego, California, United States

and more 25 locations

Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2006-10-18

Last Posted Date: 2008-11-27

Lead Sponsor: Novartis

Target Recruit Count: 150

Registration Number: NCT00389415

Locations: 🇯🇵
Novartis Pharmaceuticals, Tokyo, Japan

Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2006-10-13

Last Posted Date: 2017-02-07

Lead Sponsor: Novartis

Target Recruit Count: 726

Registration Number: NCT00387517

Locations: 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States

Efficacy and Safety of the Pediatric Formulation of Artemether- Lumefantrine in Children With Uncomplicated P. Falciparum Malaria.

Phase 3

Completed

Conditions: Malaria
Falciparum

First Posted Date: 2006-10-12

Last Posted Date: 2009-03-12

Lead Sponsor: Novartis

Target Recruit Count: 890

Registration Number: NCT00386763

Locations: 🇹🇿
Novartis, Tanzania, Tanzania

A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Aliskiren
Drug: Valsartan
Drug: Hydrochlorothiazide (HCTZ)

First Posted Date: 2006-10-11

Last Posted Date: 2014-02-10

Lead Sponsor: Novartis

Target Recruit Count: 601

Registration Number: NCT00386607

Locations: 🇳🇱
Investigative Centers, Netherlands, Netherlands

A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2006-10-11

Last Posted Date: 2017-02-07

Lead Sponsor: Novartis

Target Recruit Count: 881

Registration Number: NCT00386139

Locations: 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States

Efficacy of Fluvastatin and Fenofibrate in Comparison to Simvastatin and Ezetimibe in Patients With Metabolic Syndrome

Phase 4

Completed

Conditions: Dyslipidemia

First Posted Date: 2006-10-11

Last Posted Date: 2017-02-24

Lead Sponsor: Novartis

Target Recruit Count: 75

Registration Number: NCT00385658

Locations: 🇨🇭
Novartis Pharma AG, Basel, Switzerland

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy